The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Official Title: A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
Study ID: NCT06055959
Brief Summary: The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Detailed Description:
Minimum Age: 12 Years
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Mg0014 50574, Denton, Texas, United States
Mg0014 40144, Milano, , Italy
Mg0014 20104, Seoul, , Korea, Republic of
Mg0014 20220, Seoul, , Korea, Republic of
Name: UCB Cares
Affiliation: 001 844 599 2273
Role: STUDY_DIRECTOR